BRPI0920112A2 - derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento. - Google Patents

derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento.

Info

Publication number
BRPI0920112A2
BRPI0920112A2 BRPI0920112A BRPI0920112A BRPI0920112A2 BR PI0920112 A2 BRPI0920112 A2 BR PI0920112A2 BR PI0920112 A BRPI0920112 A BR PI0920112A BR PI0920112 A BRPI0920112 A BR PI0920112A BR PI0920112 A2 BRPI0920112 A2 BR PI0920112A2
Authority
BR
Brazil
Prior art keywords
medicament
production
cdk inhibitors
anilinopyrimidine derivatives
sulfoximine substituted
Prior art date
Application number
BRPI0920112A
Other languages
English (en)
Inventor
Gerhard Siemeister
Julia Schulze
Philip Lienau
Rolf Jautelat
Ulrich Lücking
Original Assignee
Bayer Schering Pharma Akltiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Akltiengesellschaft filed Critical Bayer Schering Pharma Akltiengesellschaft
Publication of BRPI0920112A2 publication Critical patent/BRPI0920112A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0920112A 2008-10-21 2009-10-09 derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento. BRPI0920112A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007247 WO2010046035A1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel

Publications (1)

Publication Number Publication Date
BRPI0920112A2 true BRPI0920112A2 (pt) 2015-12-22

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920112A BRPI0920112A2 (pt) 2008-10-21 2009-10-09 derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento.

Country Status (38)

Country Link
US (1) US8735412B2 (pt)
EP (2) EP2179991A1 (pt)
JP (1) JP5564054B2 (pt)
KR (1) KR20110069115A (pt)
CN (1) CN102197029B (pt)
AR (1) AR074053A1 (pt)
AU (1) AU2009306733C1 (pt)
BR (1) BRPI0920112A2 (pt)
CA (1) CA2739739C (pt)
CO (1) CO6361926A2 (pt)
CR (1) CR20110210A (pt)
CU (1) CU24052B1 (pt)
CY (1) CY1115590T1 (pt)
DK (1) DK2350026T3 (pt)
DO (1) DOP2011000107A (pt)
EA (1) EA019230B1 (pt)
EC (1) ECSP11010992A (pt)
ES (1) ES2499028T3 (pt)
HN (1) HN2011001019A (pt)
HR (1) HRP20140830T1 (pt)
IL (1) IL211713A (pt)
MA (1) MA32723B1 (pt)
MX (1) MX2011004238A (pt)
MY (1) MY155230A (pt)
NZ (1) NZ592314A (pt)
PA (1) PA8846201A1 (pt)
PE (1) PE20110546A1 (pt)
PL (1) PL2350026T3 (pt)
PT (1) PT2350026E (pt)
RS (1) RS53523B1 (pt)
SA (1) SA109300632B1 (pt)
SI (1) SI2350026T1 (pt)
TN (1) TN2011000199A1 (pt)
TW (2) TWI496774B (pt)
UA (1) UA103500C2 (pt)
UY (1) UY32190A (pt)
WO (1) WO2010046035A1 (pt)
ZA (1) ZA201103727B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
AU2013234451A1 (en) * 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
CN107001341B (zh) * 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1794134A1 (de) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
SA109300632B1 (ar) 2013-07-04
WO2010046035A1 (de) 2010-04-29
PE20110546A1 (es) 2011-08-12
MX2011004238A (es) 2011-05-23
RS53523B1 (sr) 2015-02-27
US8735412B2 (en) 2014-05-27
JP5564054B2 (ja) 2014-07-30
TWI458716B (zh) 2014-11-01
EP2350026A1 (de) 2011-08-03
CY1115590T1 (el) 2017-01-04
MA32723B1 (fr) 2011-10-02
IL211713A0 (en) 2011-06-30
SI2350026T1 (sl) 2014-10-30
EP2179991A1 (de) 2010-04-28
EA019230B1 (ru) 2014-02-28
PT2350026E (pt) 2014-09-12
AU2009306733A1 (en) 2010-04-29
UY32190A (es) 2010-05-31
CA2739739C (en) 2016-12-20
TW201444803A (zh) 2014-12-01
UA103500C2 (uk) 2013-10-25
PL2350026T3 (pl) 2014-11-28
AR074053A1 (es) 2010-12-22
AU2009306733B2 (en) 2015-11-12
US20110294838A1 (en) 2011-12-01
ECSP11010992A (es) 2011-05-31
ES2499028T3 (es) 2014-09-26
IL211713A (en) 2015-04-30
PA8846201A1 (es) 2010-05-26
HN2011001019A (es) 2013-07-01
DK2350026T3 (da) 2014-09-15
HRP20140830T1 (hr) 2014-11-21
AU2009306733C1 (en) 2016-07-14
CU20110088A7 (es) 2011-12-28
TWI496774B (zh) 2015-08-21
TN2011000199A1 (en) 2012-12-17
TW201020237A (en) 2010-06-01
EP2350026B1 (de) 2014-06-18
CU24052B1 (es) 2014-12-26
CN102197029B (zh) 2014-05-14
KR20110069115A (ko) 2011-06-22
CO6361926A2 (es) 2012-01-20
CR20110210A (es) 2011-06-08
EA201100623A1 (ru) 2011-12-30
CN102197029A (zh) 2011-09-21
ZA201103727B (en) 2014-11-26
JP2012506391A (ja) 2012-03-15
NZ592314A (en) 2013-02-22
DOP2011000107A (es) 2011-05-15
CA2739739A1 (en) 2010-04-29
MY155230A (en) 2015-09-30

Similar Documents

Publication Publication Date Title
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0815773A2 (pt) composto, e, medicamento.
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0907381A2 (pt) Derivados de carboxamidas azabicíclicos, o respectivo preparo e a respectiva aplicação em terapêutica.
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0923828A2 (pt) método de produção de isopreno e um co-produto.
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0914802A2 (pt) Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0918430A2 (pt) 4-fenil-1h-pirazóis inseticidas.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
ZA201103727B (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
BRPI1014583A2 (pt) sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo.
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI1015943A8 (pt) derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
BRPI1016192A2 (pt) derivados de soxazol.
BRPI0906727A2 (pt) Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
BRPI0816679A2 (pt) Derivados de ftalazinona.
BRPI0907487A2 (pt) Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]